PharmacyCodes



Oxaprozine [Inn-French] en es it fr

Categorie

Oxaprozine [Inn-French] Les marques, Oxaprozine [Inn-French] Analogs

Oxaprozine [Inn-French] Les marques melange

  • No information avaliable

    • Oxaprozine [Inn-French] Formule chimique

    C18H15NO3

    Oxaprozine [Inn-French] RX lien

    http://www.rxlist.com/cgi/generic/oxaproz.htm

    Oxaprozine [Inn-French] FDA fiche

    Oxaprozine_[Inn-French] FDA

    Oxaprozine [Inn-French] msds (fiche de securite des materiaux)

    Oxaprozine_[Inn-French] MSDS

    Oxaprozine [Inn-French] Synthese de reference

    Aucune information disponible

    Oxaprozine [Inn-French] Poids moleculaire

    293.317 g/mol

    Oxaprozine [Inn-French] Point de fusion

    158 - 159 oC

    Oxaprozine [Inn-French] H2O Solubilite

    Insolubles

    Oxaprozine [Inn-French] Etat

    Solid

    Oxaprozine [Inn-French] LogP

    4.8

    Oxaprozine [Inn-French] Formes pharmaceutiques

    Tablet

    Oxaprozine [Inn-French] Indication

    Utilisé pour soulager l'inflammation, l'enflure, la raideur et des douleurs articulaires associées à l'arthrite rhumatoïde et l'arthrose.

    Oxaprozine [Inn-French] Pharmacologie

    Oxaprozine est un médicament anti-inflammatoires non stéroïdiens (AINS) avec des propriétés analgésiques et antipyrétiques. Oxaprozine est utilisé pour traiter l'arthrite rhumatoïde, l'arthrose, la dysménorrhée, et pour soulager la douleur modérée.

    Oxaprozine [Inn-French] Absorption

    Oxaprozine est de 95% après administration orale. Les aliments peuvent réduire le taux d'absorption de l'oxaprozine, mais le degré d'absorption est inchangé. Les antiacides ne modifient pas sensiblement l'ampleur et la vitesse d'absorption de l'oxaprozine.

    Oxaprozine [Inn-French] Toxicite

    Oral, souris: DL50 = 1210 mg / kg; orale, lapin: DL50 = 172 mg / kg; voie orale, rat: DL50 = 4470 mg / kg

    Oxaprozine [Inn-French] Information pour les patients

    Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up.

    Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

    Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

    Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

    In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the ductus arteriosus.

    Oxaprozine [Inn-French] Organismes affectes

    Les humains et autres mammifères